CordenPharma, a full-service CDMO, has announced the completed acquisition of three manufacturing facilities from Vifor Pharma, to be renamed Corden Pharma Fribourg (including its Ettingen branch) in Switzerland, and Corden Pharma Lisbon in Portugal.
Acquisition of the manufacturing sites will expand the company’s capabilities in non-sterile drug product dosage forms, including but not limited to, oral solid dosage forms such as tablets and capsules. With the addition of these three facilities, the company's global network now consists of twelve locations, supported by more than 2600 employees.
Dr Michael Quirmbach, CEO & President of CordenPharma said: “We welcome the three sites and their employees as new members to the CordenPharma Group and look forward to working with Vifor in the future to supply Vifor Pharma’s finished drug products, including to their already existing customers. The acquired pharma sites have a well-trained workforce with great cultural fit, state-of-the art infrastructure, and a strong compliance track record. This excellent opportunity aligns well with our strategy to broaden our CDMO capabilities.”
